

Dino J. Gonzalez, MD

Office Addresses:

1712 Bearden
Las Vegas, NV 89106
Voice- (702) 360-5439
Fax- (702) 361-8000
Email- dinogmd@hotmail.com

Southwest Medical Associates
2316 W Charleston Blvd. Suite 265
Las Vegas, NV 89102
Voice- (702) 877-5319
Fax- (702) 877-5342

Wellness Center
2300 S. Rancho Dr. Suite 205
Las Vegas, NV 89102
Voice- (702) 383-2691
Fax- (702) 388-4114

Nevada Access to Research and Education Society
Nevada AIDS Research and Education Society
2300 S. Rancho Dr. Suite 203
Las Vegas, NV 89102
Voice- (702) 384-9101
Fax- (702) 384-9109

Personal Data

Languages Spoken: English, Spanish

Hospital Affiliation

University Medical Center	Las Vegas, NV
Valley Hospital	Las Vegas, NV
Summerlin Hospital	Las Vegas, NV
Mountain View Hospital	Las Vegas, NV

Education, Degrees and Awards

1988 - 1993	University of Nevada, Las Vegas Las Vegas, NV B.S. Chemistry, Biology Minor
1994 - 1998	University of Nevada School of Medicine Reno, NV Medical School

Education, Degrees and Awards

- | | |
|-------------|---|
| 1998 - 2001 | University of Nevada School of Medicine
Las Vegas, NV
Internal Medicine, Internship and Residency |
| 2001 | Diplomat, American Board of Internal Medicine |

Licensure

Nevada Medical License # 9912

Professional Certifications

- | | |
|----------------|--|
| 2002 - Present | Certified HIV Specialist
American Academy of HIV Medicine |
| 2001 - 2011 | Diplomat, American Board of Internal Medicine |

Chronology of Work Experience

- | | |
|----------------|--|
| 2003 – Present | Nevada Access to Research and Education Society
Nevada AIDS Research and Education Society
Las Vegas, NV |
| 2002 - Present | Assistant Medical Director HIV Inpatient Unit
University Medical Center of Southern Nevada
Las Vegas, NV |
| 2001- Present | Wellness Center, Las Vegas, NV |
| 2001 - Present | Private Practice, Las Vegas, NV |
| 1993 - 1994 | Toxicology Technologist II. Associated Pathologist
Laboratories |

Academic Appointments

- | | |
|----------------|--|
| 2006 – Present | Clinical Associate Professor
Department of Internal Medicine
University of Nevada School of Medicine |
|----------------|--|

Professional Societies and Organizations

American Academy of HIV Medicine (AAHIVM)

Research

TMC114-C226. Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

TMC114-C211. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. ARTEMIS TRIAL. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

HPR20001. A phase IIb, randomized, multicenter, parallel group study to evaluate the short-term safety, pharmacokinetics and antiviral activity of four blinded dosing regimens of GW640385/ritonavir therapy compared to open-label current protease inhibitor therapy in HIV-1 infected, protease inhibitor experienced adults for 2 weeks with long-term evaluation (>48 weeks) of safety, pharmacokinetic and antiviral activity of selected GW640385/ritonavir dosing regimen(s) vs. a ritonavir-boosted, protease inhibitor containing regimen. GlaxoSmithKline. Investigator. October 2005.

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subjects with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistant virus. GlaxoSmithKline. Investigator. July 2005.

CCR102881. A phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults. GlaxoSmithKline. Investigator. March 2005.

BI1182.70. An open label, nonrandomized treatment protocol of Tipranavir co-administered with low-dose Ritonavir (TPV/r) in protease inhibitor-experienced patients with HIV-1 infection (the Tipranavir Expanded Access Program). Boehringer Ingelheim. Investigator. December 2004.

Research

Protocol ML18018. A 12-week, prospective, open-label, multicenter, cohort, study to assess HIV-patient QUALITY of Life and Tolerability after administration of Enfuvirtide-containing HAART (QUALITE). Roche. Principal Investigator. December 2004.

COL102060. An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of Abacavir 600 mg/Lamivudine 300 mg once-daily in combination with Atazanavir 300 mg + Ritonavir 100 mg once-daily in antiretroviral-naïve HIV-1 infected subjects over 48 weeks. GlaxoSmithKline. Investigator. October 2004.

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. Investigator. July 2004.

D5896C00005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of Symbicort^R pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair^R in subjects 12 years and older with asthma. AstraZeneca. Investigator. January 2004.

MK-038. A multicenter, randomized, double-blind, placebo-controlled, “factorial” design study to evaluate the lipid-altering efficacy and safety of ezetimibe/simvastatin combination tablet in patients with primary hypercholesterolemia. Merck. Investigator. 2003.

A3841012. Clinical utility of amlodipine/atorvastatin to improve concomitant cardiovascular risk factors of hypertension and dyslipidemia (Gemini). Pfizer. Investigator. 2003.

066-00. A randomized, double-blind, active-comparator-controlled, parallel-group study to evaluate the safety of etoricoxib in patients with osteoarthritis or rheumatoid arthritis. Merck. Investigator. 2003.

C02-009. A phase III, randomized, multicenter, allopurinol and placebo-controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout. TAP Pharmaceuticals. Investigator. 2003.

Research

CVAH631C2301. A 54-week open-label extension to a randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Investigator. 2003.

BY217/M2-023. A randomized, controlled study of roflumilast (250mcg and 500mcg) versus placebo in patients with asthma. A 24-week, multinational, double-blind, parallel group clinical study. Altana. Investigator. 2003.

BI1182.58. An open label safety study to evaluate the safety of tipranavir plus ritonavir when used in combinations with other agents for the treatment of patients with HIV infection who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. April 2003.

CCIB002K2302. A randomized, double-blind, multicenter, positive controlled, parallel group study to evaluate the safety and efficacy of Lotrel (amlodipine/benazepril) compared to Zestoretic (lisinopril/hydrochlorothiazide) in hypertensive patients. Novartis. Investigator. January 2003.

BI1182.51. An open label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

MEM-MD-06B. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Investigator. 2002.

AI424900. Atazanavir (BMS-232632) for HIV infected individuals: An early access program. Bristol-Myers Squibb. Investigator. July 2002.

ESS40013. A Phase IV Multicenter Study of the Efficacy and Safety Of 48-Week Induction Treatment with Trizivir + Efavirenz Followed by 48-Week Randomized, Open-Label Maintenance Treatment with Trizivir ± Efavirenz in HIV-1 Infected ART Naïve Subjects. GlaxoSmithKline. Investigator Mar 2001.

Research

MV16812. Multicenter, open-label, early access program of fuzeon (enfuvirtide) T-20/Ro29-9800, HIV-1 Fusion Inhibitor) in combination with free choice antiretroviral regimen to assess serious adverse events, serious AIDS defining events and tolerability in patients with advanced HIV-infection. F. Hoffmann-LaRoche LTD, Trimeris Inc., Investigator.

AI424-045. A randomized, open label study of the antiviral efficacy and safety of atazanavir, in combination with ritonavir or saquinavir, and the combination of lopinavir each with tenofovir and a nucleoside in subjects who have experienced virologic failure. Bristol-Myers Squibb. Investigator April 2002.

BI1182.17. A long term open label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator August 2002.

CLAF237A 2203. A 12 week, multicenter, double-blind, randomized, parallel-group, dose-ranging study to assess the efficacy, safety and tolerability of LAF237 25mg bid, 25mg, 50mg, 100mg qd compared to placebo in patients with type 2 diabetes. Novartis. Investigator.

HMR3647A/3014. Randomized, open-label, multicenter trial of the safety and effectiveness of Oral Telithromycin (Ketek) and amoxicillin/clavulanic acid (Augmentin) in outpatients with respiratory tract infections in usual care settings. Aventis Pharmaceuticals, Inc. Investigator. 2002.

N49-01-02. clinical protocol for the assessment of the efficacy of treatment by Celecoxib 200mg QD and 400mg QD on the symptoms of ankylosing spondylitis compared to naproxen and placebo. Investigator. Pharmacia. 2002.

NAVIGATOR Nateglinide/CDJN608B. A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2 X 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance. Novartis. Investigator. 2002.

CFOR258D2307. A randomized, multicenter, placebo controlled, parallel group study, of four month duration per patient, to evaluate the safety and efficacy of treatment with 24mcg bid and 12mcg bid formoterol double blind and 12mcg bid formoterol with additional on demand formoterol doses open label in adolescent and adult patients with persistent stable asthma. Novartis. Investigator. April 2002.

Investigation of the possible role of α TNF in reperfusion injury. University of Nevada School of Medicine, Las Vegas, NV. Investigator. 1995.

References available by request